Bronchiectasis Clinical Trials

Find Bronchiectasis Clinical Trials Near You

A Phase 1 First-In-Human, Double-Blind, Single and Multiple Ascending Dose Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous Doses of CTX-187 in Healthy Volunteers Followed by Multiple Doses in Patients With a Bacterial Infection

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Parts A and B: Healthy adult males and/or females, 18 to 65 years of age.

• Parts A and B: Body mass index (BMI): ≥18.0 and ≤32.0 kg/m\^2 and weight \>50 kg.

• Parts A and B: Good physical and mental health without clinically significant abnormalities.

• Part C: Adult males and/or females, 18 to 75 years of age.

• Part C: Prior clinical and computerized tomography diagnosis of bronchiectasis.

• Part C: P. aeruginosa in sputum, bronchoalveolar lavage or another airway sample at least once in the 12 months prior to screening and P. aeruginosa in sputum during screening, both of which should be at least 21 days apart.

• Part C: Otherwise in good physical and mental health without clinically significant abnormalities.

Locations
Other Locations
Netherlands
ICON Clinic, location GRQM
RECRUITING
Groningen
Contact Information
Primary
Centauri Clinical Team
clinical@centauritherapeutics.com
Please use email
Time Frame
Start Date: 2026-06-16
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 104
Treatments
Experimental: Part A (Single Ascending Dose [SAD]): CTX-187
Healthy participants will receive a single IV infusion of CTX-187 in escalating doses.
Placebo_comparator: Part A (SAD): Placebo
Healthy participants will receive a single IV infusion of matching placebo.
Experimental: Part B (Multiple Ascending Dose [MAD]): CTX-187
Healthy participants will receive multiple escalating doses of CTX-187 via IV infusion twice daily (BID) for 7 days.
Placebo_comparator: Part B (MAD): Placebo
Healthy participants will receive matching placebo via IV infusion BID for 7 days.
Experimental: Part C (MAD in Participants with a Bacterial Infection): CTX-187
Participants with a bacterial infection will receive multiple escalating doses of CTX-187 via IV infusion BID for 6 days (Days 2 to 7) with a single dose on Day 1 and Day 8.
Placebo_comparator: Part C (MAD in Participants with a Bacterial Infection): Placebo
Participants with a bacterial infection will receive matching placebo via IV infusion BID for 6 days (Days 2 to 7) with a single dose on Day 1 and Day 8.
Related Therapeutic Areas
Sponsors
Leads: Centauri Therapeutics Limited

This content was sourced from clinicaltrials.gov

Similar Clinical Trials